Bruker at EuPA 2026: Proteomics 2.0 - From Biosamples to Bioinsights
Proteomics 2.0: From Biosamples to Bioinsights
Meet Bruker at EuPA 2026 in Würzburg, Germany, November 29 - December 3, and explore how next-generation mass spectrometry is helping researchers address key challenges in translational proteomics, immunopeptidomics, glycoproteomics, proteoform research, and biomarker discovery.
Learn how innovative workflows are enabling researchers to transform complex biological data into actionable research findings. Connect with our experts, explore the latest innovations in proteomics, and join our Lunch Seminars on November 30 and December 1 to hear leading scientists share their latest research and real-world applications.
Throughout the week, visit Booth 10 to discuss your research challenges with our experts and learn about technologies designed to support deeper and more comprehensive proteome characterization.
Join Our Lunch Seminars
Monday Seminar: Advanced Translational Proteomics for Precision Medicine Research
- November 30, 2026 | 11:45–12:45 CET | Room 13
- Hear leading researchers discuss how advanced proteomics workflows are supporting translational studies, biomarker discovery, immunopeptidomics, and tissue proteomics.
Tuesday Seminar: Continuous Innovation: Revealing What Lies Beyond the Amino Acid Sequence
- December 1, 2026 | 11:45–12:45 CET | Room 13
- Discover innovative approaches that reveal biological information beyond conventional protein identification, from top-down proteomics and glycoproteomics to high-throughput MALDI-TOF workflows.
Advanced Translational Proteomics: Paving the Way for Supporting Precision Medicine Research
Driven by the latest technological advances, including trapped ion mobility spectrometry (TIMS), LC–MS-based proteomics now delivers the reliability, robustness, depth, and throughput required to address major challenges in translational research and advance personalized medicine.
This seminar will explore how high-quality proteomic data can be translated into actionable biological and clinical research insights to support translational investigations. Through complementary perspectives spanning immunopeptidomics and the sensitive identification of endogenous neoantigens from limited clinical material, biofluid and plasma proteomics for biomarker discovery in rare diseases, and deep proteome profiling of tumor tissues, including formalin-fixed, paraffin-embedded samples, the session will illustrate how advanced proteomics can reveal disease mechanisms, support cohort stratification in research studies, and support future translational and clinical research efforts.
Featured Presentations:
- TCR Target Deconvolution Using High-Throughput Immunopeptidomics
Stefan Tenzer, Ph.D., Professor for Immunoproteomics, University Medical Center of the Johannes Gutenberg University Mainz, Germany - From Molecular Signatures to Actionable Insights
Chiara Guerrera, IRHC, HDR, Head of the Necker Proteomics, SFR Necker, Paris, France - Integrating Mass Spectrometry-Based Proteomics into Clinical Molecular Tumor Profiling: Experience of Over 600 Cases
Oliver Schilling, Ph.D., Professor, University of Freiburg, Institute of Surgical Pathology, FFPE Proteomics, Freiburg, Germany
Seminar Details:
- Date: Monday, November 30, 2026
- Time: 11:45 - 12:45 CET
- Location: Congress Center Würzburg, Room 13
Stefan Tenzer, Ph.D.
Professor for Immunoproteomics
University Medical Center of the Johannes Gutenberg University Mainz
Mainz, Germany
Chiara Guerrera, IRHC, HDR
Head of the Necker Proteomics
SFR Necker
Paris, France
Oliver Schilling, Ph.D.
Professor
University of Freiburg, Institute of Surgical Pathology, FFPE Proteomics
Freiburg, Germany
Continuous Innovation: Revealing What Lies Beyond the Amino Acid Sequence
Proteomics offer a distinct advantage over genomics and transcriptomics by directly measuring proteins, the dynamic molecular effectors of biological function. Yet, traditional hardware and software constraints have often restricted analysis to the most readily accessible information: proteins are typically digested into peptides to match the optimal mass-to-charge range of mass spectrometers, complex post-translational modifications may remain unresolved, and limited throughput can constrain cohort size.
This session will showcase innovative approaches that extract more actionable biological insight from proteins and their molecular diversity.
Our speakers will demonstrate how ultrafast proteome profiling can be achieved with accessible instrumentation and how glycopeptide profiling and characterization, together with top-down proteomics, are moving beyond proof-of-concept studies toward applications in complex, biologically relevant samples. By revealing post-translational modifications and intact proteoforms that conventional bottom-up workflows may overlook, these advances are expanding the discovery potential of proteomics.
Featured Presentations:
- Top-Down Characterization of Circulating Antibodies
Julia Chamot-Rooke, Ph.D., CNRS Senior Scientist, Head of the MSBio Unit at Institut Pasteur, Paris, France - Myriad2: Hypothesis-Free Glycan Topology Identification for Glycoproteomics
Hans Wessels, Ph.D., Director Radboud Technology Center for Mass Spectrometry, Radboud UMC, Nijmegen, Netherlands - Machine Learning-Enabled High-Throughput exoBAMS-MALDI-TOF Profiling of EV-Derived Molecular Signatures from Liquid Biopsy Samples Using the neofleX™ benchtop MALDI-TOF
Arndt Asperger, Ph.D., Pharma Applications, Bruker Daltonics, Bremen, Germany
Seminar Details:
- Date: Tuesday, December 1, 2026
- Time: 11:45 - 12:45 CET
- Location: Congress Center Würzburg, Room 13
Julia Chamot-Rooke, Ph.D.
CNRS Senior Scientist, Head of the MSBio Unit
Institut Pasteur
Paris, France
Hans Wessels, Ph.D.
Director Radboud Technology Center for Mass Spectrometry
Radboud UMC
Nijmegen, Netherlands
Arndt Asperger, Ph.D.
Pharma Applications
Bruker Daltonics
Bremen, Germany
Register Now for the Bruker Lunch Seminars at EuPA 2026
See how next-generation mass spectrometry is advancing translational proteomics and deeper biological insight.
Disclaimer
As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.
* Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a nongovernmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.
** A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.
研究用にのみ使用できます。臨床診断には使用できません。